Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | BUB1 | O43683 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29519648 | 1.00 | KMT2A (0.54) | KMT2ABUB1ALDH1A1FAAHMTNR1A | |
| SCHEMBL29882799 | 0.87 | MTNR1A (0.53) | KMT2AALDH1A1FAAHMTNR1AMTNR1B | |
| SCHEMBL4432302 | 0.87 | MTNR1A (0.53) | KMT2AALDH1A1FAAHMTNR1AMTNR1B | |
| SCHEMBL15519819 | 0.84 | KMT2A (0.56) | KMT2ABUB1ALDH1A1BRD4TSHR | |
| SCHEMBL8911487 | 0.84 | KMT2A (0.56) | KMT2ABUB1ALDH1A1BRD4TSHR | |
| SCHEMBL17540272 | 0.83 | KMT2A (0.44) | KMT2ABUB1ALDH1A1HSD11B1TSHR | |
| SCHEMBL12472574 | 0.82 | FAAH (0.55) | KMT2AFAAHNPY5R | |
| SCHEMBL1339793 | 0.81 | KMT2A (0.46) | KMT2AMTNR1AMTNR1BMEN1SMN1; SMN2 | |
| SCHEMBL31278113 | 0.81 | KMT2A (0.46) | KMT2ABUB1ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL9979464 | 0.81 | CA1 (0.46) | KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002002119-A1 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-10 | — | — | WO | claimed |
| US-12559455-B2 | Compound as a UBR box domain ligand | AUTOTAC INC. (KR) | 2026-02-24 | — | — | US | disclosed |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-12286411-B2 | Indane derivatives for use in the treatment of bacterial infection | ANTABIO SAS (FR) | 2025-04-29 | — | — | US | disclosed |
| US-12247013-B2 | Indane derivatives for use in the treatment of bacterial infection | ANTABIO SAS (FR) | 2025-03-11 | — | — | US | disclosed |
| WO-2024163752-A1 | HETEROCYCLIC COMPOUNDS AS PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-4408416-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2024-08-07 | — | — | EP | disclosed |
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-4689339-A | 4-dihydroinden-2-yl-, 4-tetrahydronaphth-2-yl-, and 4-dihydrobenzofuran-2-ylimidazoles, useful to block α2 -adrenergic receptors | FARMOS YHTYMA OY (FI) | 1987-08-25 | — | — | US | disclosed |
| EP-0183492-A1 | Substituted imidazole derivatives and their preparation and use | Farmos-Yhtyma Oy (FI) | 1986-06-04 | — | — | EP | disclosed |
| EP-0056271-B1 | CARBOXYLIC ACID ESTERS AND INSECTICIDAL AND/OR ACARICIDAL COMPOSITIONS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-05-07 | — | — | EP | disclosed |
| US-4559356-A | ANTIDE PRESSANTS; HYPERTENSIVE AGENTS | SYNTHELABO (FR) | 1985-12-17 | — | — | US | disclosed |
| US-4480118-A | Carboxylic acid ester and an insecticidal and/or acaricidal composition containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-10-30 | — | — | US | disclosed |
| EP-0056271-A2 | Carboxylic acid esters and insecticidal and/or acaricidal compositions | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-07-21 | — | — | EP | disclosed |
| US-4269848-A | ANTIINFLAMMATORY AGENTS; ANALGESICS; ANTIPYRETICS | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1981-05-26 | — | — | US | disclosed |
| US-4224341-A | ANTIINFLAMMATORY AGENTS, ANALGESICS AND ANTIPYRETICS | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1980-09-23 | — | — | US | disclosed |
| US-4166131-A | ANTIINFLAMMATORY AGENTS, ANTIPYRETICS, ANTIARTHRITIC AGENT | HEXACHIMIE SOCIETE ANONYME (FR) | 1979-08-28 | — | — | US | disclosed |
| US-4152527-A | 15-Substituted-ω-pentanorprostaglandins | PFIZER INC. (US) | 1979-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12286411-B2 | Indane derivatives for use in the treatment of bacterial infection | ELANE, ARG1, INSRR | KMT2A 3671/4885BUB1 908/4885ALDH1A1 1376/4885 |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | KMT2A 12/4885BUB1 661/4885ALDH1A1 4369/4885 |
| US-12030862-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, PIK3R4, PIK3R5 | KMT2A 4426/4885BUB1 1179/4885ALDH1A1 3412/4885 |
| US-12559455-B2 | Compound as a UBR box domain ligand | UBR4, UBTF, UBQLN1 | KMT2A 574/4885BUB1 2220/4885ALDH1A1 1486/4885 |
| US-12247013-B2 | Indane derivatives for use in the treatment of bacterial infection | ELANE, ARG1, INSRR | KMT2A 3671/4885BUB1 908/4885ALDH1A1 1376/4885 |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | KMT2A 12/4885BUB1 661/4885ALDH1A1 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.